当前位置:首页 >英文主页 >中英对照 > 中译版报告详情

德勤:2024年全球生命科学行业展望报告-变中求进 韧而有为(中译版)(118页).pdf

上传人: Kell****reet 编号:167971 2024-07-11 118页 5.56MB

下载:

1、Driving resiliency2024 Global Life Sciences Sector Outlook2ContentsIntroduction 3Value creation:M&A,partnerships,collaborations,new sources of capital,and shifting portfolios 5Extracting value from Generative AI and emerging technologies 17Pricing pressures rising globally,threats of impacts on R&D

2、innovation worldwide 31Accelerating speed of time to value in R&D 48Shifting trends in openness:Globalization vs.localization and impacts for multinational companies 60Achieving better patient outcomes with personalized experiences and shared decision-making 75Contacts 90Learn more 92Endnotes 943Int

3、roductionIntroductionWith the global pandemic firmly in the rearview mirror,life sciences companies are looking at key macro-and micro-economic drivers to guide their future growth.While the list of trends with wide-ranging global impact is broad,in this year,life sciences enterprises are paying par

4、ticular attention to those more disruptive trends including increasing pricing pressures and changes in United States regulation,the acceleration of Generative AI(GenAI)adoption and impact,the geo-political environment,and as always,breakthrough science and outcomes.Companies are exploring how the e

5、volution of GenAI can impact their operations and determining where to focus first and how to generate differential value.The potential of advanced technologies and these collaborations are directly integrated with life sciences companies overall efforts to improve patient outcomes and inform their

6、R&D decisions.Companies are looking to the potential of GenAI to bring more value across the boardboth in terms of cost reduction and revenue uplift.GenAI and other AI technologies,coupled with digital transformation tools,are poised to increase overall efficiencies and process innovation across man

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要概括了2024年全球生命科学行业的展望。关键点包括: 1. 生命科学公司正在关注宏观和微观经济驱动因素,以指导其未来增长。 2. 2023年,大型制药公司通过大规模并购(M&A)展示了其购买力,其中肿瘤学领域吸引了最多的投资。 3. 预计2024年,制药公司将继续通过战略并购来填补因专利到期而产生的产品线缺口。 4. 医疗技术(MedTech)和诊断领域的并购活动在2023年有所下降,但预计2024年将出现积极的反转。 5. 私募股权(PE)在生命科学领域的投资在2021年达到峰值,2023年出现了一些大规模交易,但整体筹资环境变得更加困难。 6. 风险投资(VC)在生命科学初创公司的交易继续放缓,但仍高于大流行前水平。 7. 生命科学公司正探索生成性人工智能(GenAI)的潜力,以提高研发效率,降低成本,并改善患者结果。 8. 生命科学公司正面临全球定价压力上升的挑战,这可能对研发创新产生影响。 9. 生命科学公司正致力于通过个性化的体验和共享决策来改善患者结果。
2024年生命科学行业并购趋势如何? 人工智能和生成式AI如何影响生命科学行业? 2024年全球药品定价压力将如何影响生命科学公司?
客服
商务合作
小程序
服务号
折叠